Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Panel 2: phase II investigations.

L E Hollister, B L Martz, E A Carr

    Clinical Pharmacology and Therapeutics
    |November 1, 1975
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    First Report of Bulb Disease of Onion Caused by Pantoea ananatis in New York.

    Plant disease·2019
    Same author

    Cervical vertebral canal endoscopy in a horse with cervical vertebral stenotic myelopathy.

    Equine veterinary journal·2011
    Same author

    Cervical vertebral canal endoscopy in the horse: intra- and post operative observations.

    Equine veterinary journal·2011
    Same author

    Carcinoma of the islets of Langerhans with hyperinsulinism; report of a case.

    The New England journal of medicine·2010
    Same author

    A rapid bedside test for the detection of hypoglycemia.

    The Journal of laboratory and clinical medicine·2010
    Same author

    Airway inflammation in Michigan pleasure horses: prevalence and risk factors.

    Equine veterinary journal·2006
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Reply to: "The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient".

    Clinical pharmacology and therapeutics·2026
    Same journal

    Ruxolitinib Pharmacokinetics and Exposure-Toxicity Relationship in Hematologic Malignancies and Immune-Mediated Diseases: A Prospective Observational Study.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Repurposing Registries: Completeness of Real-World Data for Regulatory and HTA Purposes in Three Cancer-Focused Registries.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Phase II studies are critical for therapeutic drug development decisions. Expert judgment and careful planning are essential for successful progression to clinical therapeutics.

    Area of Science:

    • Pharmaceutical Sciences
    • Clinical Trials
    • Drug Development

    Background:

    • The conclusion of Phase II clinical trials necessitates a critical decision regarding a drug's therapeutic potential.
    • This decision extends beyond scientific data, requiring significant expert judgment.

    Purpose of the Study:

    • To emphasize the pivotal role of Phase II studies in the drug development pipeline.
    • To highlight the need for meticulous planning and high-caliber investigators in Phase II studies.
    • To address the imbalance in drug development efforts driven by escalating costs and easily defined endpoints.

    Main Methods:

    • Expert evaluation of scientific data from Phase II studies.
    • Strategic planning for subsequent drug development phases.

    Related Experiment Videos

  • Assessment of therapeutic needs versus easily defined study endpoints.

    • Main Results:

    • Phase II studies represent the most crucial stage for determining a drug's therapeutic viability.
    • Careful planning and execution by top investigators are paramount for successful Phase II outcomes.
    • Escalating development costs are shifting focus towards studies with simpler endpoints, potentially at the expense of true therapeutic needs.

    Conclusions:

    • Decisions to advance drugs into further development rely heavily on expert judgment informed by Phase II results.
    • Prioritizing therapeutic needs in drug development is essential, requiring collaboration between industry, academia, and regulatory bodies like the FDA.
    • Facilitating studies addressing critical therapeutic advances should be a shared concern for all stakeholders in drug development.